Polyethyleneglycol modified scutellarin compound and preparation thereof

A technology of scutellarin and polyethylene glycol, which is applied in the field of PEG-modified prodrugs and its preparation, can solve the problems of research, low solubility, no pharmacokinetics and pharmacodynamics, etc., to improve water solubility, The effect of enhancing biological activity

Inactive Publication Date: 2009-07-22
JIANGSU SIMCERE PHARMA +1
View PDF2 Cites 16 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Although scutellarin has great application value and economic benefits, there are obvious disadvantages in its wide application: the solubility of scutellarin in water is low (0.056mg/ml), and the half-life is short (3-4 minutes). Poor

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Polyethyleneglycol modified scutellarin compound and preparation thereof
  • Polyethyleneglycol modified scutellarin compound and preparation thereof
  • Polyethyleneglycol modified scutellarin compound and preparation thereof

Examples

Experimental program
Comparison scheme
Effect test

Example Embodiment

[0110] Example 1: Synthesis of scutellarin-polyethylene glycol (400) monomethyl ether-6"-ester (compound I-400)

[0111]

[0112] Add scutellarin 9.24g, mPEG(400)12g, HOBt4.05g, DCC6.18g (molar ratio 1:1.5:1.5:1.5) into 80mL DMF to dissolve, pass nitrogen to protect the reaction system, and heat to 40℃ Reaction for 6 hours, TLC detects the end of the reaction (CH 2 Cl 2 :CH 3 OH:HCOOH=10:1:0.2). After the reaction is complete, add water to terminate the reaction, filter out part of the solid, and concentrate the filtrate under reduced pressure to distill off DMF and water. The crude product of viscous substance is subjected to CH 2 Cl 2 :CH 3 The eluent of OH:HCOOH=10:1:0.1 was separated and purified through a silica gel column three times to obtain 7.65 g of a pale yellow powdered solid with a yield of 45.3%.

[0113] 1H NMR (DMSO-d6, 300MHz): δH 6.81 (1H, S, C 3 -H), 7.00(1H, S, C 8 -H), 7.93 (2H, d, J=8.9 Hz, C 2’,6’ -H), 6.96 (2H, d, J=8.9 Hz, C 3’,5’ -H), 5.20 (1H, d, J=6.8...

Example Embodiment

[0115] Example 2: Synthesis of scutellarin-polyethylene glycol (600) monomethyl ether-6"-ester (compound I-600)

[0116] Add scutellarin 13.86g, mPEG(600)27g, HOBt6.07g, DCC9.27g (molar ratio 1:1.5:1.5:1.5) into 120mL of DMF to dissolve, protect the reaction system with nitrogen, and heat to 45℃ Reaction for 8 hours, TLC detects the end of the reaction (CH 2 Cl 2 :CH 3 OH:HCOOH=10:1:0.2). After the reaction is completed, add water to terminate the reaction, filter out part of the solid, concentrate the filtrate under reduced pressure to distill off DMF and water, and pass the crude product of viscous substance to CH 2 Cl 2 :CH 3 The eluent of OH:HCOOH=10:1:0.1 was separated and purified through a silica gel column three times to obtain 12.62 g of light yellow powdery solid, with a yield of 40.3%.

[0117] 1 H NMR (DMSO-d6, 300MHz): δH 6.81 (1H, S, C3-H), 7.00 (1H, S, C 8 -H), 7.93 (2H, d, J=8.9 Hz, C 2’,6’ -H), 6.96 (2H, d, J=8.9 Hz, C 3’,5’ -H), 5.20 (1H, d, J=6.8, C 1” -H), 4.21...

Example Embodiment

[0119] Example 3: Synthesis of scutellarin-polyethylene glycol (1000) monomethyl ether-6"-ester (compound I-1000)

[0120] Add scutellarin 9.24g, mPEG(1000)30g, HOBt4.05g, DCC6.18g (molar ratio 1:1.5:1.5:1.5) into 150mL DMF to dissolve, pass nitrogen to protect the reaction system, and heat to 50℃ Reaction for 10 hours, TLC detects the end of the reaction (CH 2 Cl 2 :CH 3 OH:HCOOH=10:1:0.2). After the reaction is complete, add water to terminate the reaction, filter out part of the solid, concentrate the filtrate under reduced pressure to distill off DMF and water, and pass the viscous crude product through CH 2 Cl 2 :CH 3 The eluent of OH:HCOOH=10:1:0.1 was separated and purified through a silica gel column three times to obtain 10.54 g of a light yellow powdered solid with a yield of 36.5%.

[0121] 1 H NMR (DMSO-d6, 300MHz): δH 6.82 (1H, S, C3-H), 7.03 (1H, S, C8-H), 7.94 (2H, d, J=8.9 Hz, C2', 6'- H), 6.95 (2H, d, J=8.9 Hz, C3', 5'-H), 5.27 (1H, d, J=6.8, C1"-H), 4.21 (1H, d, ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a PEGylated scutellarin compound and a preparation method thereof. The PEGylated scutellarin compound is as the shown formula (IV) and the PEGylated scutellarin compound can be applied to preparing medicaments applied to treating cerebral thrombosis, cerebral infarction, cerebral apoplexy, sequelaes caused by cerebral apoplexy, coronary heart disease or angina. Compared with the original scutellarin compound, the water solubility of the scutellarin compound is increased obviously; simultaneously, pharmacodynamics experiment on the mice model of cerebral ischemia-reperfusion shows that: compared with the original medicament, the biological activity of the scutellarin promedicament is strengthened obviously.

Description

technical field [0001] The invention belongs to the field of medicinal chemistry, and in particular relates to a PEG-modified prodrug, a preparation method and application thereof. Background technique [0002] Scutellarin, that is, 4', 5, 6-trihydroxyflavone-7-glucuronide, has the functions of scavenging active oxygen, dilating blood vessels, increasing cardiac coronary flow, increasing cerebral blood flow, and reducing cerebrovascular It can be used for cardiovascular and cerebrovascular diseases, such as cerebral infarction, post-stroke hemiplegia, coronary heart disease, angina pectoris, etc., with good curative effect. And it has been used clinically for more than 20 years, and no serious side effects have been found. Its existing preparations include common tablets, injections and injection powders. [0003] Although scutellarin has great application value and economic benefits, there are obvious disadvantages in its wide application: the solubility of scutellarin in...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07H17/07C08G65/34A61K31/7048A61K31/765C07H1/00A61P9/10A61P9/00
Inventor 成昌梅王义明赵兴俄路娟胡跃飞华垚王森檀爱民
Owner JIANGSU SIMCERE PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products